• Neurogene priced a public offering expected to raise about USD 125 million in gross proceeds.
• Deal includes 3,500,000 common shares at USD 30 per share.
• Also issued pre-funded warrants for 666,666 shares at USD 30 each; exercise price USD 0.000001 per share.
• Closing expected July 2, 2026, subject to customary conditions.
• Underwriters hold a 30-day option to buy up to 624,999 additional shares.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Neurogene Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202607010700BIZWIRE_USPR_____20260630_BW424924) on July 01, 2026, and is solely responsible for the information contained therein.